Novel multi-strain probiotics reduces *Pasteurella multocida* induced fowl cholera mortality in broilers

Rine Christopher Reuben1,2, Shovon Lal Sarkar1, Habiba Ibnat1, Md. Ali Ahasan Setu1, Pravas Chandra Roy1 & Iqbal Kabir Jahid1*

*Pasteurella multocida* causes fowl cholera, a highly contagious poultry disease of global concern, causing significant ecological and economic challenges to the poultry industry each year. This study evaluated the effects of novel multi-strain probiotics consisting of *Lactobacillus plantarum*, *L. fermentum*, *Pediococcus acidilactici*, *Enterococcus faecium* and *Saccharomyces cerevisiae* on growth performance, intestinal microbiota, haematobiochemical parameters and anti-inflammatory properties on broilers experimentally challenged with *P. multocida*. A total of 120 birds were fed with a basal diet supplemented with probiotics (10⁸ CFU/kg) and then orally challenged with 10⁸ CFU/mL of *P. multocida*. Probiotics supplementation significantly (P < 0.05) improved growth performance and feed efficiency as well as reducing (P < 0.05) the population of intestinal *P. multocida*, enterobacteria, and mortality. Haematobiochemical parameters including total cholesterol, white blood cells (WBC), proteins, glucose, packed cell volume (PCV) and lymphocytes improved (P < 0.05) among probiotic fed birds when compared with the controls. Transcriptional profiles of anti-inflammatory genes including hypoxia inducible factor 1 alpha (HIF1A), tumor necrosis factor- (TNF) stimulated gene-6 (TSG-6) and prostaglandin E receptor 2 (PTGER2) in the intestinal mucosa were upregulated (P < 0.05) in probiotics fed birds. The dietary inclusion of the novel multi-strain probiotics improves growth performance, feed efficiency and intestinal health while attenuating inflammatory reaction, clinical signs and mortality associated with *P. multocida* infection in broilers.

*Pasteurella multocida* is a Gram-negative coccobacillus and readily transmitted bacterium which causes fowl or avian cholera, an acute and fatal septicemic infection affecting wide range of both wild and domestic bird species12. In poultry, it causes significant economic loss on back-yard and large-scale commercial poultry production globally13. Although not common, human cases of *P. multocida* infections are often associated with immunosuppressed individuals, older adults or rarely due to occupational exposure5,6. The route of infection and pathogenesis of *P. multocida* in poultry have not been clearly elucidated, however, accumulated evidence suggests the respiratory tract as the major entry point1. Furthermore, *P. multocida* is known to be normal microflora of the upper respiratory tract (URT) of most healthy animals including poultry, and it can inhabit the oropharynx of healthy hosts for elongated periods without causing disease2. However, virulent strains of *P. multocida* are able to colonize the mucosa of the upper respiratory tract and, subsequently, infect the air sacs and lungs of birds. Through an unknown mechanism, but possibly related to the migration in macrophages of the upper respiratory tract, the bacteria can access the blood circulation from the mucosa and multiply in different tissues, especially in the liver and spleen2,4.

In the poultry industry, antibiotics have been used over the years in the treatment and control of poultry infections and in some countries also as growth promoters. The control of *P. multocida* infections in poultry using antibiotics has been somewhat successful, nevertheless, there is often relapse after antibiotic withdrawal. More so, 80.5% of *P. multocida* infections have shown high degree of resistance to broad range of commonly used antibiotics7,8. Strains of *P. multocida* from ducks, chickens, geese, turkeys and quails have reportedly shown resistance to doxycycline-HCl, enrofloxacin, chloramphenicol, norfloxacin and lincomycin13,18.

1Department of Microbiology, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore 7408, Bangladesh. 2German Centre for Integrative Biodiversity Research (iDiv), Halle-Jena-Leipzig, Germany. *email: i.kjahid_mb@just.edu.bd
With the phasing out of antibiotics in animal production due to immense public health concerns including the presence of drug residue in animal products, emergence and spread of resistance, dysbiosis of gut microflora and hypersensitivity among others, there is need for the application of naturally safe alternatives which will both improve animal growth performance as well as control infectious diseases. Probiotics, which are now widely accepted as alternatives to antibiotics, are viable microorganisms which confer wide range of nutritional and health benefits in animals when administered in sufficient amount. Probiotics ameliorate enteric infections through competitive exclusion of pathogens, and chronic inflammatory and allergic diseases, as well as immunomodulation and immune-stimulation, increased digestibility and nutrients assimilation in their host.

The regular inclusion of probiotics in poultry diets may both minimize the risk of infections with pathogens such as *P. multocida*, *E. coli*, *Campylobacter spp.*, *Listeria monocytogenes* and *Salmonella* as well as improving growth performance in birds. This would significantly decrease the risks associated with poultry and poultry product contamination with animal pathogens of public health concern, hence reducing human spread as well as safeguarding the environment.

Recently, several successful reports have emerged on the treatment of poultry infections and multidrug-resistant bacterial pathogens using probiotic strains. Up to date, apart from few field studies on the effectiveness of antibiotic alternatives such as bacteriophages, vaccines, β-glucan, and certain proteins against *P. multocida* infections, no study has evaluated the effectiveness of probiotics in ameliorating infections caused by *P. multocida* in poultry despite its devastating effects in the poultry industry. Being known as an ‘inscrutable’ pathogen, some strains of *P. multocida* have the potential of colonizing the nasopharynx, respiratory and the gastrointestinal tracts of animals including poultry thereby inducing severe disease. The use of probiotics in mitigating infection caused by *P. multocida*, which is rarely regarded as a gut-associated pathogen, would further aid in reducing the intestinal colonization and/or severity infection by other gut-associated and opportunistic pathogens.

In our previous studies, strains of LAB (lactic acid bacteria) were isolated, characterized and evaluated for antagonistic activity against poultry pathogens and in vitro probiotic properties. We hypothesized that dietary multi-strains probiotic supplementation would improve the growth performance, modulate intestinal microflora and haematobiological parameters as well as ameliorate *P. multocida* infection in broiler chickens. This study aimed to investigate the effect of dietary supplementation with novel multi-strain probiotic (consisting of *Lactobacillus plantarum*, *L. fermentum*, *Pediococcus acidilactici*, *Enterococcus faecium* and *Saccharomyces cerevisiae*) on the growth performance, intestinal microflora, haematobiological parameters and anti-inflammatory properties on *P. multocida* infection in broilers.

**Results**

**Growth performance.** From the beginning of this experimental trial, i.e., days 1 to 14, no statistically significant (P > 0.05) differences were recorded in the body weight (BW), body weight gain (BWG), feed intake (FI) and feed conversion ratio (FCR) among all the treatments. The FCR differs significant (P < 0.05) between the probiotic supplemented groups (Pro− and Pro+) when compared with the with the NC− while other groups showed non-significantly higher values (Table 1). During the post—*P. multocida* challenge period, i.e., days 14 to 28, probiotics supplementation significantly (P < 0.05) affected growth performance and feed utilization (Table 1). There was severe depression in the growth, FI and FCR in the NC+ and PC+ treatments in the first- and second-week post infection compared with other treatments. In general, probiotics supplemented groups, with or without *P. multocida* challenged showed significantly (P < 0.05) higher BW and BWG compared to others at the end of the experiment. Birds in the challenged positive control (PC+) and the challenged negative control (NC+) treatments had the worse BW, BWG and FCR compared to others from day 21 onwards (Table 1).

**Clinical signs and mortality.** In a pilot study to determine the infectivity, broilers were challenged with *P. multocida* and the clinical signs and death due to *P. multocida* were recorded (data not shown). Severe pasteurellosis due to the experimental inoculation of birds with *P. multocida* was initially induced in the NC− group and later in the PC+ group about 12 and 24 h post-challenged (Fig. 1). Clinical signs manifested in challenged birds included diarrhea, depression, severe weakness, nasal discharge, isolation, reduction in feed and water consumption, ruffled feathers, immobility and lameness which are the characteristics of *P. multocida* infection in poultry (Fig. 1). Although the most severe clinical manifestations recorded in this study were observed between 24 to 94 h post-infection, mild to moderate clinical signs persist in the challenged groups (PC+ and NC+) until the end of the experiment while no obvious clinical signs were observed in challenged probiotic (Prob+) group (Fig. 1). At the end of the trial, mortality rates attributed to *P. multocida* infection were 5.00, 60.00 and 65.00% for Pro+, PC+ and NC+ treatments respectively (Table 2). Mortality was significantly higher (P < 0.05) in birds in the PC+ and NC+ groups when compared with the Pro+ group. Similarly, the highest mortality recorded due to *P. multocida* occurred during the first 72 h post-infection, with 10 and 8 mortalities in PC+ and NC+ groups while the lone mortality recorded in Prob+ throughout the entire study occurred on 72 h post infection (Table 2).

**Carcass and visceral organs weight.** On day 21 of the experiment, the relative weight of the Bursa in the probiotics supplemented birds (Pro− and Pro+) were significantly (P < 0.05) higher when compared to birds in other treatments, with the NC− having the least weight of 0.09 g as recorded. Similarly, the relative weight of ileum in Prob+ group differed significantly (P < 0.05) when compared with other *P. multocida* challenged groups (PC+ and NC+), and non challenged groups (PC− and NC−) (Table 3). The relative weights of the wing and dressing carcass recorded from birds in Pro− and Pro+ groups were significantly (P < 0.05) higher than NC+. Furthermore, whereas the relative weight of the liver from birds in Pro− group was significantly higher than birds from all the groups except Pro+ (which was numerically higher) on day 28, the relative weight of the spleen in
Table 1. Effects of probiotics supplementation on growth performance of *Pasteurella multocida* challenged broiler chickens. Values are means of two replicates and standard errors of means. Within each variable, values with the same superscript letter are not significantly different according to Duncan’s multiple range test (P > 0.05). NC−: unchallenged negative control; PC−: unchallenged positive control; Pro−: unchallenged probiotics control; Pro+: challenged probiotic control; PC+: challenged positive control; NC+: challenged negative control; BW−: body weight; BWG−: body weight gain; F−: feed intake; FCR: feed conversion ration.

| Growth performance | Treatment          | NC− expect. | PC− expect. | Pro− expect. | Pro+ expect. | PC+ expect. | NC+ expect. | SEM | P value |
|--------------------|--------------------|-------------|-------------|-------------|-------------|-------------|-------------|-----|---------|
| BW 1 (g)           |                   | 47.00a      | 46.86a      | 46.55a      | 46.95a      | 47.05a      | 46.75a      | 0.145 | 0.071   |
| BW 7 (g)           |                   | 143.85b     | 139.05b     | 145.7a      | 141.1a      | 142.7a      | 142.65a     | 0.931 | 0.087   |
| BWG (g)            |                   | 96.85c      | 92.45c      | 99.15c      | 94.15c      | 95.25c      | 96.1c       | 0.941 | 0.999   |
| FI (g)             |                   | 231.2       | 239.2       | 234.45a     | 238.15a     | 253.7a      | 230.1a      | 3.520 | 0.105   |
| FCR                |                   | 2.385a      | 2.587a      | 2.365a      | 2.529a      | 2.664a      | 2.394a      | 0.051 | 0.083   |
| BW 14 (g)          |                   | 324.2d      | 329.9d      | 356.45e     | 352.16e     | 338.7d      | 320.7d      | 6.024 | 0.041   |
| BWG (g)            |                   | 277.2b      | 283.67b     | 309.9a      | 305.15b     | 291.25a     | 274.15a     | 6.005 | 0.050   |
| FI (g)             |                   | 435.5a      | 405a        | 410.5a      | 401.4a      | 400.6a      | 397.8a      | 5.694 | 0.012   |
| FCR                |                   | 1.571a      | 1.428a      | 1.325b      | 1.315b      | 1.375b      | 1.451b      | 0.039 | 0.031   |
| BW 21 (g)          |                   | 621.65a     | 631.69b     | 687.2a      | 651.26b     | 426.36c     | 414.89c     | 48.811 | 0.015   |
| BWG (g)            |                   | 574.65a     | 585.11c     | 640.65a     | 604.21b     | 379.81a     | 368.11a     | 48.792 | 0.032   |
| FI (g)             |                   | 957.00a     | 903.58d     | 804.07e     | 701.11d     | 641.73c     | 662.44c     | 53.643 | 0.029   |
| FCR                |                   | 1.665a      | 1.544d      | 1.255a      | 1.160a      | 1.690b      | 1.799c      | 0.105 | 0.044   |
| BW 28 (g)          |                   | 989.22a     | 942.18d     | 1201.72a    | 1195.71b    | 612.38a     | 582.57a     | 110.928 | 0.009   |
| BWG (g)            |                   | 942.22a     | 895.58d     | 1155.17a    | 1148.76a    | 564.93a     | 536.02a     | 110.969 | 0.010   |
| FI (g)             |                   | 1139.55b    | 993.59d     | 1096.53a    | 999.05b     | 865.17c     | 699.46c     | 65.883 | 0.011   |
| FCR                |                   | 1.209a      | 1.109b      | 0.949b      | 0.870b      | 1.531c      | 1.305e      | 0.099 | 0.025   |

Figure 1. Symptoms in *Pasteurella multocida* challenged groups supplemented with antibiotic (PC+) and control (NC+); (A) Yellowish-grey diarrhoea appeared on the cloaca, (B) Yellowish-grey diarrhoea appeared on the cloaca and littered, (C) Depression and isolation, (D) Moribund, lameness and ruffled feathers, (E) Healthy and active probiotics supplemented broilers challenged with *Pasteurella multocida* (Pro+), (F) Healthy and active probiotics supplemented broilers challenged with *Pasteurella multocida* (Pro+).
the NC+ and PC− groups were significantly lower when compared with other groups. Also, although the dressing carcass of the PC− group was significantly (P < 0.05) higher than all other groups (except Pro+), the dressing carcass of birds in the Pro+ group similarly had significantly (P < 0.05) higher relative weight when compared with other challenged groups (PC+ and NC+). (Table 3). The relatively weights of carcass and visceral organs from the Pasteurella multocida challenged groups generally had the least values especially from birds in the NC+ group.

Enumeration of intestinal digesta intestinal bacteria, yeast and P. multocida. There was no significant (P > 0.05) differences in the numbers of total aerobes from the ileal and caecal contents on day 21 of the trial among all the treatments. However, the LAB counts in the gizzard contents of probiotics supplemented birds (groups Pro− and Pro+) was significant (P < 0.05) higher on day 28 when compared with other groups (Table 4). Also, the LAB counts in the ileum and caecum of birds from PC+ and NC+ were lower (P < 0.05) than probiotics supplemented birds (groups Pro− and Pro+). The numbers of enterobacteria recorded from the gizzard, ileum and caecum on day 21 of the trial were significantly (P < 0.05) higher in P. multocida challenged groups, PC+ and NC+, when compared with other treatments, and this trend persist till the end of the trial. The numbers of yeast cells tended to be higher in the ileum and caecum of birds supplemented probiotics than other groups. However, the least yeast counts were recorded from the gizzards of all the birds across the treatments with birds in PC+ and NC+ groups having a significantly (P < 0.05) lowered counts on day 21.

Throughout this experimental trial, birds in the probiotic control, Pro+ treatment had significantly (P < 0.05) lowered counts of P. multocida in their gizzards, ilea and caeca when compared with those of birds in the other challenged treatments, PC+ and NC+ respectively (Table 4). Whereas the gizzards of birds in the probiotic control treatment, Pro+ had the least counts of P. multocida, 0.50 log10CFU/g on day 21, significantly higher counts of P. multocida ranging between 6.62 and 7.01 log10CFU/g were recorded from the ilea and caeca of birds in the PC+ and NC+ treatments on day 28 of the trial. The numbers of P. multocida in the ileal and caecal contents were significantly (P < 0.05) reduced in Pro+ group when compared with other challenged groups, PC+ and NC+ on days 21 and 28 (i.e., 7 and 14 days post-challenged) respectively. Birds from all the treatments were confirmed to be culture-negative for Pasteurella before inoculation with P. multocida on day 14 of the experiment. Also, the non-P. multocida challenged treatments (i.e., NC−, PC− and Pro−) were Pasteurella negative throughout the experimental period.

Intestinal digesta pH. Generally, this study recorded an increasing pH concentration from acidity to neutrality with the gizzard digesta of birds having the lowest pH levels followed by the ileal and then the caecal contents respectively (Table 5). The pH of the ileal contents from birds in PC+ groups were significantly (P < 0.05) lowered when compared with other challenged groups, PC+ and NC+ on days 21 and 28 respectively.

Haemato-biochemical parameters. The total cholesterol concentration in birds from the probiotics supplemented groups, Pro− and Pro+ were significantly (P < 0.05) lower than P. multocida challenged groups, PC+ and NC+ on days 21 and 28 of the experiment. Nevertheless, there was no significant (P > 0.05) difference in the HDL cholesterol and LDL cholesterol concentrations across the treatment all through the experiment. On day 28, while triglyceride levels were reduced (P > 0.05) in probiotics supplemented groups but higher (P < 0.05)
in NC−, glucose levels were significantly (P < 0.05) reduced in the same groups. Similarly, protein levels were significantly (P < 0.05) higher in probiotics supplemented groups when compared with other groups on day 28 (Table 6).

The results of the haematogical parameters analyzed are shown in Table 7. Whereas no difference (P > 0.05) was recorded in total RBC, haemoglobin, ESR, PCV, basophiles, monocytes, total platelet count and MPV across the treatments on day 21, statistical difference were recorded for total WBC and neutrophils between the probiotics supplemented groups when compared with other treatments. Nevertheless, on day 28 of the experiment MCV and RDW were significantly (P > 0.05) higher in probiotics supplemented groups Pro− and Pro+ when compared with non-P. multocida challenged negative control group, NC−. Also, probiotics supplemented birds with or without P. multocida challenge significantly (P < 0.05) increased total WBC counts at the end of the trial. Also, the concentrations of lymphocytes and monocytes were higher in probiotics supplemented groups while PC− and Prob− had higher (P > 0.05) total platelet counts on day 28 of the experiment.

**Anti-inflammatory gene expression.** On 14-day post P. multocida challenged, dietary supplementation of birds with probiotics significantly (P < 0.05) upregulated the mRNA profiles of anti-inflammatory genes including HIF1A (hypoxia inducible factor 1 alpha) and TSG-6 (Tumor necrosis factor- (TNF) stimulated gene-6) on the caecal mucosa when compared to the birds in the control group (Table 8). However, when both anti-inflammatory genes are compared, probiotic effect in the upregulating the expression of HIF1A was higher than for PTGER2. There was no difference in the expression of both anti-inflammatory genes in birds supplemented with antibiotic and the negative control except for TSG-6 (Table 8).

| Organ   | Treatment | NC− | PC− | Pro− | Pro+ | PC+ | NC+ | SEM | P value |
|---------|-----------|-----|-----|------|------|-----|-----|-----|---------|
| Heart   | 0.74      | 0.54 | 0.74 | 0.72 | 0.69 | 0.53 | 0.04 | 0.298   |
| Liver   | 2.08      | 2.36 | 2.99 | 3.29 | 2.77 | 2.53 | 0.17 | 0.107   |
| Spleen  | 0.11      | 0.17 | 0.25 | 0.19 | 0.13 | 0.09 | 0.03 | 0.929   |
| Bursa   | 0.12      | 0.13 | 0.30 | 0.35 | 0.18 | 0.09 | 0.04 | 0.021   |
| Gizzard | 3.46      | 3.11 | 3.54 | 3.82 | 3.56 | 3.61 | 0.09 | 0.183   |
| Ileum   | 2.99      | 2.24 | 2.57 | 3.53 | 2.75 | 2.73 | 0.20 | 0.021   |
| Caecum  | 0.57      | 0.46 | 0.58 | 0.71 | 0.63 | 0.38 | 0.04 | 0.092   |
| Thigh   | 4.77      | 4.02 | 4.07 | 4.28 | 4.42 | 4.25 | 0.11 | 0.202   |
| Drumstick | 4.34  | 3.63 | 3.86 | 3.58 | 3.34 | 3.41 | 0.14 | 0.075   |
| Breast  | 19.57     | 20.15 | 21.98 | 19.60 | 17.30 | 13.75 | 1.06 | 0.041   |
| Wing    | 2.13      | 1.81 | 2.67 | 2.02 | 1.90 | 1.56 | 0.09 | 0.012   |
| Dressing| 55.07     | 54.62 | 61.47 | 57.53 | 45.22 | 41.37 | 1.72 | 0.023   |

**Table 3.** Relative weights (% BW) of organs from broilers supplemented with probiotics and challenged with *Pasteurella multocida*. Values are means of two replicates and standard errors of means. Within each variable, values with the same superscript letter are not significantly different according to Duncan's multiple range test (P > 0.05). NC−: unchallenged negative control; PC−: unchallenged positive control; Pro−: unchallenged probiotics control; Pro+: challenged probiotic control; PC+: challenged positive control; NC+: challenged negative control.
Discussion
Avian cholera caused by *P. multocida* is a highly contagious poultry disease of global concern, causing significant ecological and economic challenges to the poultry industry each year. The ability of *P. multocida* to survive asymptomatically in carrier birds for a longer period of time even after the disappearance of clinical signs has often led to frequent recurrence of *P. multocida* outbreaks with high mortality. Also, *P. multocida* has been reported to persist for several months in the environment, water supplies, and insects. In this study, we proposed that the supplementation of poultry with multistrain probiotics containing *L. plantarum*, *L. fermentum*, *P. acidilactici*, *E. faecium* and *S. cerevisiae* can control *P. multocida* infection in broiler chickens through mitigating the manifestation of clinical signs and the reduction of mortality associated with *P. multocida* while improving the overall performance.

Table 4. Microbial counts (Log_{10} cfu/g) in the digesta of chickens supplemented with probiotics and challenged with *Pasteurella multocida*. Values are means of two replicates and standard errors of means. Within each variable, values with the same superscript letter are not significantly different according to Duncan’s multiple range test (P > 0.05). NC−: unchallenged negative control; PC−: unchallenged positive control; Pro−: unchallenged probiotics control; Pro+: challenged probiotic control; PC+: challenged positive control; NC+: challenged negative control.
Although some studies have previously tried the effectiveness of vaccines as antibiotic alternatives in the control of *P. multocida* in poultry, studies evaluating the possible role of probiotics in the control of *P. multocida* colonization and infections in poultry production are lacking. With the successful reports of probiotics effectiveness in the control and mitigation of the colonization and infection by poultry pathogens including *Salmonella*14,28,29, *Campylobacter*15,30,31, *E. coli*32,33, *Eimeria* spp.34,35, *L. monocytogenes*36–38 and *Clostridium perfringens*39,40, the trial of probiotics in the control of *P. multocida* would further unravel probiotics effectiveness against this devastating poultry pathogen.

Generally, the dietary supplementation of probiotics has been reported to positively influence animal health and productivity. The results obtained from this study shows that dietary inclusion of probiotics significantly improved the performance and feed efficiency in broiler chickens with beneficial impact on the intestinal microbiota composition and health, hence decreasing the severity of the FC in birds. The significant improvement in BW, BWG and FCR recorded among broilers supplemented with probiotics in comparison with the controls from this study confirmed the positive impact of probiotics supplementation on the performance of broilers. This finding is significant not only to confirm the improvement of intestinal health after probiotic supplementation, but also to mitigate the economic losses due to *P. multocida* infections in poultry production. Our results agreed with the findings of Smialet et al., Massacci et al., Mountzouris et al., Olnood et al. who reported significantly improved growth performance and feed efficiency of probiotics supplemented broilers challenged with either

**Table 5.** Effects of supplementation with probiotics and challenged with *Pasteurella multocida* on pH of GIT of broilers. Values are means of two replicates and standard errors of means. Within each variable, values with the same superscript letter are not significantly different according to Duncan’s multiple range test (P > 0.05). NC−: unchallenged negative control; PC−: unchallenged positive control; Pro−: unchallenged probiotics control; Pro+: challenged probiotic control; PC+: challenged positive control; NC+: challenged negative control.

| Parameter | Treatment | NC− | PC− | Pro− | Pro+ | PC+ | NC+ | SEM | P-value |
|-----------|-----------|-----|-----|------|------|-----|-----|-----|---------|
| Day 21    | Gizzard   | 3.53<sup>a</sup> | 3.84<sup>b</sup> | 3.18<sup>a</sup> | 3.38<sup>a</sup> | 3.75<sup>b</sup> | 4.1<sup>a</sup> | 0.137 | 0.057   |
|           | ileum     | 5.62<sup>a</sup> | 5.83<sup>b</sup> | 4.71<sup>b</sup> | 3.93<sup>a</sup> | 5.7<sup>a</sup> | 5.61<sup>b</sup> | 0.298 | 0.021   |
|           | Caeicum   | 6.47<sup>a</sup> | 6.14<sup>a</sup> | 6.17<sup>a</sup> | 5.89<sup>a</sup> | 6.04<sup>a</sup> | 6.27<sup>a</sup> | 0.139 | 0.287   |
| Day 28    | Gizzard   | 3.63<sup>a</sup> | 3.80<sup>a</sup> | 3.01<sup>a</sup> | 2.95<sup>a</sup> | 3.76<sup>a</sup> | 3.65<sup>a</sup> | 0.155 | 0.093   |
|           | ileum     | 5.73<sup>a</sup> | 5.97<sup>a</sup> | 5.36<sup>a</sup> | 5.09<sup>a</sup> | 5.71<sup>a</sup> | 6.05<sup>a</sup> | 0.119 | 0.026   |
|           | Caeicum   | 7.15<sup>a</sup> | 6.72<sup>a</sup> | 6.43<sup>a</sup> | 6.31<sup>a</sup> | 6.64<sup>a</sup> | 6.85<sup>a</sup> | 0.115 | 0.105   |

**Table 6.** Effects of probiotics supplementation on biochemical parameters of *Pasteurella multocida* challenged broiler chickens. Values are means of two replicates and standard errors of means. Within each variable, values with the same superscript letter are not significantly different according to Duncan’s multiple range test (P > 0.05). NC−: unchallenged negative control; PC−: unchallenged positive control; Pro−: unchallenged probiotics control; Pro+: challenged probiotic control; PC+: challenged positive control; NC+: challenged negative control. *HDL* high density lipid, *LDL* low density lipid, *RISK* total cholesterol-HDL ratio.

| Parameter | Treatment | NC− | PC− | Pro− | Pro+ | PC+ | NC+ | SEM | P-value |
|-----------|-----------|-----|-----|------|------|-----|-----|-----|---------|
| Day 21    | Total cholesterol (mg/dL) | 92<sup>a</sup> | 94.04<sup>b</sup> | 74.00<sup>c</sup> | 81.5<sup>a</sup> | 111<sup>c</sup> | 108<sup>a</sup> | 4.333 | 0.024   |
|           | HDL cholesterol (mg/dL)    | 76<sup>c</sup> | 74<sup>c</sup> | 72.5<sup>c</sup> | 82.5<sup>c</sup> | 91<sup>c</sup> | 93<sup>c</sup> | 4.197 | 0.095   |
|           | LDL cholesterol (mg/dL)    | 26<sup>c</sup> | 20.5<sup>c</sup> | 24.5<sup>c</sup> | 22<sup>c</sup> | 24<sup>c</sup> | 25.5<sup>c</sup> | 0.864 | 0.217   |
|           | Triglyceride (mg/dL)       | 56.5<sup>c</sup> | 60<sup>c</sup> | 54.5<sup>c</sup> | 52<sup>c</sup> | 70<sup>c</sup> | 60<sup>c</sup> | 3.829 | 0.089   |
|           | Total cholesterol-HDL ratio | 1.18<sup>a</sup> | 1.25<sup>a</sup> | 1.23<sup>a</sup> | 1.23<sup>a</sup> | 1.22<sup>a</sup> | 1.16<sup>a</sup> | 0.014 | 0.101   |
|           | Total protein (g/dL)       | 2.53<sup>a</sup> | 2.88<sup>a</sup> | 3.26<sup>b</sup> | 2.95<sup>a</sup> | 2.52<sup>a</sup> | 2.25<sup>a</sup> | 0.114 | 0.021   |
|           | Glucose (mmol/L)           | 12.34<sup>a</sup> | 13.65<sup>a</sup> | 11.12<sup>a</sup> | 11.38<sup>a</sup> | 14.18<sup>a</sup> | 13.64<sup>a</sup> | 0.386 | 0.082   |
| Day 28    | Total cholesterol (mg/dL)  | 100.5<sup>c</sup> | 110.5<sup>c</sup> | 76.5<sup>c</sup> | 79<sup>c</sup> | 105.5<sup>c</sup> | 107<sup>c</sup> | 5.581 | 0.031   |
|           | HDL cholesterol (mg/dL)    | 66<sup>c</sup> | 91<sup>c</sup> | 68<sup>c</sup> | 73.5<sup>c</sup> | 73<sup>c</sup> | 86<sup>c</sup> | 4.098 | 0.097   |
|           | LDL cholesterol (mg/dL)    | 28.6<sup>c</sup> | 30.5<sup>c</sup> | 20.7<sup>c</sup> | 27<sup>c</sup> | 37.5<sup>c</sup> | 31.5<sup>c</sup> | 2.260 | 0.310   |
|           | Triglyceride (mg/dL)       | 113.5<sup>c</sup> | 111.5<sup>c</sup> | 71.5<sup>c</sup> | 91<sup>c</sup> | 103<sup>a</sup> | 105<sup>a</sup> | 9.681 | 0.021   |
|           | Total cholesterol-HDL ratio | 1.27<sup>c</sup> | 1.21<sup>c</sup> | 1.09<sup>c</sup> | 1.20<sup>c</sup> | 1.27<sup>c</sup> | 1.26<sup>c</sup> | 0.027 | 0.472   |
|           | Total protein (g/dL)       | 2.81<sup>c</sup> | 2.89<sup>c</sup> | 3.64<sup>c</sup> | 3.51<sup>c</sup> | 2.25<sup>c</sup> | 2.38<sup>c</sup> | 0.232 | 0.009   |
|           | Glucose (mmol/L)           | 12.21<sup>c</sup> | 15.05<sup>c</sup> | 9.04<sup>c</sup> | 8.17<sup>c</sup> | 13.87<sup>c</sup> | 12.22<sup>c</sup> | 0.434 | 0.026   |
Campylobacter and Salmonella respectively. Furthermore, apart from the adoption of biosecurity measures and vaccination (which are most potent preventive measures) in endemic regions of the world, the routine use of probiotics in the control and prevention of enteric infections in poultry production could further help in reducing the severity of cases of fowl cholera hence, diminishing the spread of the pathogen.

Changes in the relative weight of visceral organs and carcass in broilers is one principal effect mostly attributed to probiotic supplementation in poultry. The symptoms of pasteurellosis in the *P. multocida* challenged positive control (PC+) and negative control (NC+) were accompanied by decrease in the live BW of birds, visceral organs and dressing carcass in these treatments with higher increase in gizzard weights on day 28 of the experiment. These trends were similarly reported previously by Olnood et al., and Park and Kim, after experimentally infecting broiler chickens with *Salmonella* spp.41,42. The improved growth performance of birds due to

### Table 7. Effects of probiotics supplementation on haematological parameters of *Pasteurella multocida* challenged broiler chickens. Values are means of two replicates and standard errors of means. Within each variable, values with the same superscript letter are not significantly different according to Duncan’s multiple range test (P > 0.05). NC−: unchallenged negative control; PC−: unchallenged positive control; Pro−: unchallenged probiotics control; Pro+: challenged probiotic control; PC+: challenged positive control; NC+: challenged negative control.

| Parameter          | Treatment | NC−  | PC−  | Pro− | Pro+ | NC+ | SEM  | P value |
|--------------------|-----------|------|------|------|------|-----|------|---------|
| **RBC**            |           |      |      |      |      |     |      |         |
| Total RBC (mil/Cmm) | Day 21    | 1.68a| 2.59a| 2.71a| 2.48a| 2.62a| 2.17a| 0.158   | 0.310  |
| Total RBC (mil/Cmm) | Day 28    | 2.08a| 3.07a| 3.08a| 2.78a| 2.615| 2.65a| 0.150   | 0.107  |
| **Haemoglobin (g/dL)** |           | 6.65a| 7.58a| 7.45a| 7.64a| 7.3a | 6.75a| 0.318   | 0.092  |
| **ESR (mm/1 h)**   |           | 3a  | 2a  | 3a  | 4a  | 2a  | 3.5a | 0.327   | 0.420  |
| **PCV (%)**        |           | 22.15a| 33.4a| 36.7a| 34.3a| 35.4a| 29a  | 2.212   | 0.198  |
| **MCV (fl)**       |           | 130.4a| 129.2a| 142.1a| 144.25a| 135.45a| 134.05a| 2.677   | 0.032  |
| **MCH (pg)**       |           | 34.15a| 30.2a| 32.4a| 33a  | 28.05a| 31.14a| 0.891   | 0.024  |
| **MCHC (g/dL)**    |           | 26.25a| 23.35a| 22.45a| 22.9a | 20.65a| 23.2a | 0.741   | 0.040  |
| **RDW (%)**        |           | 9.35a| 9.35a| 11.85a| 10.15a| 12.95a| 9.75a  | 0.609   | 0.022  |
| **WBC**            |           |      |      |      |      |     |      |         |
| Total WBC (C/mm)   |           | 63845| 171760| 233860| 266850| 123320| 110985| 15,785.2| 0.001  |
| Neutrophils (%)    |           | 40.5a| 36.5a| 34a  | 32.00a| 23.2a | 30a  | 5.567   | 0.013  |
| Lymphocytes (%)    |           | 57a  | 59.5a| 80a  | 91.8a | 73a  | 58.4a | 6.167   | 0.036  |
| Monocytes (%)      |           | 1a   | 0.5a | 2a   | 2.5a  | 1a   | 1a   | 0.307   | 0.415  |
| Basophiles (%)     |           | 0.5a | 0.5a | 0.67a| 1.27a | 0.75a | 0.78a | 0.196   | 0.172  |
| Platelets          |           |      |      |      |      |     |      |         |
| Total platelet count (C/mm) |           | 3500a| 2500a| 2350a| 2200a| 2000a| 2500a| 202.76  | 0.113  |
| **MPV (fl)**       |           | 8.9a | 7.9a | 10.8a| 11.45a| 11.65a| 10.55a| 0.609   | 0.081  |
| **Day 28**         |           |      |      |      |      |     |      |         |
| RBC                |           |      |      |      |      |     |      |         |
| Total RBC (mil/Cmm) | Day 21    | 2.08a| 3.07a| 3.08a| 2.78a| 2.615| 2.65a| 0.150   | 0.107  |
| Total RBC (mil/Cmm) | Day 28    | 8.97a| 10.61a| 10.98a| 11.38a| 11.70a| 9.54a | 0.437   | 0.031  |
| Haemoglobin (g/dL) |           | 6.51a| 6.65a| 8.79a| 7.77a| 6.58a| 6.22a| 0.230   | 0.035  |
| ESR (mm/1 h)       |           | 3a   | 2a   | 3a   | 4a   | 2a   | 3.5a | 0.327   | 0.195  |
| PCV (%)            |           | 28.15a| 30.4a| 36.7a| 34.05a| 31.25a| 25.63a| 1.383   | 0.004  |
| MCV (fl)           |           | 129.8a| 135.15a| 148.20a| 141.80a| 135.59a| 126.9a| 3.312   | 0.026  |
| MCH (pg)           |           | 32.75a| 29.3a| 31.26a| 33.2a | 27.04a| 30.16a| 0.938   | 0.387  |
| MCHC (g/dL)        |           | 23.45a| 23.19a| 22.75a| 24.1a | 24a  | 23.26a| 0.210   | 0.410  |
| RDW (%)            |           | 8.97a| 10.61a| 10.98a| 11.38a| 11.70a| 9.54a | 0.437   | 0.031  |

**WBC**

| Parameter          | Treatment | NC−  | PC−  | Pro− | Pro+ | NC+ | SEM  | P value |
|--------------------|-----------|------|------|------|------|-----|------|---------|
| Total WBC (C/mm)   |           | 172070| 202866| 302440| 346652| 235780| 223933| 26,314.05| 0.001  |
| Neutrophils (%)    |           | 39a  | 39.5a| 35a  | 37a  | 31.5a| 38.5a| 1.243   | 0.201  |
| Lymphocytes (%)    |           | 52.5a| 57.7a| 88.6a| 93.5a| 67a  | 55.75a| 7.566   | 0.021  |
| Monocytes (%)      |           | 0.75a| 1a   | 2.5a  | 3.5a  | 1.25a| 0.75a | 0.338   | 0.023  |
| Basophiles (%)     |           | 1a   | 0.5a | 1.25a| 1.02a | 1a   | 0.75a | 0.106   | 0.719  |
| Platelets          |           |      |      |      |      |     |      |         |
| Total platelet count (C/mm) |           | 4000a| 5500a| 7500a| 5250a| 3750a| 2750a| 681.35  | 0.019  |
| **MPV (fl)**       |           | 11.25a| 9.1a | 9.95a| 10.85a| 11.15a| 11.95a| 0.417   | 0.231  |
probiotic supplementation as observed in the current study was also reported by other researchers after challenging broilers with different pathogens. The dietary supplementation of broilers with B. subtilis as probiotic significantly increased the relative weight of spleen by 3.8% without significantly affecting the relative weights of liver and bursa of Fabricius43. In agreement with our study, Pedroso et al. reported that the dietary inclusion of Lactobacillus reuteri and L. johnsonii as probiotics significantly increased intestinal weight in 21-day old broilers44. Probiotics effect on the weight of visceral organs and intestines of animals is inexplicit, and can also be determined by the nature and amount of microbial strains used as probiotics. It has been reported that probiotics consistently influence the intestinal morphology and micro-structure which often increases the absorptive function of the ileum14,45. Also, Pelicano et al. reported significant improvement in the leg yield and breast of birds fed with probiotics46.

A significantly higher mortality was recorded in P. multocida challenged birds supplemented with antibiotic and challenged negative control when compared with the P. multocida challenged birds supplemented with probiotic. The change in behavior and the manifestation of clinical signs in the control groups were consistent with the reported signs characterizing fowl cholera in poultry such as diarrhoea, depression, listlessness, severe weakness, nasal discharge, recumbency and moribund status, isolation, anorexia combined with reduction in feed and water consumption, ruffled feathers, immobility and lameness4,22,23. Within 24 h post-challenging broilers with different pathogens. The dietary supplementation of broilers with multi-strain probiotics containing a strain causing the infection which may also influence the shedding and isolation of the pathogen2,47,50. The persistence of P. multocida strains at the site of infection as well as their migration to other host tissues and organs, and the eventual time of the host death depend primarily on the host immune response and the characteristics of P. multocida strain causing the infection which may also influence the shedding and isolation of the pathogens2,47,50. The inhibitory effect of each of the probiotic strain i.e. L. plantarum, L. fermentum, P. acidilactici, E. faecium and S. cerevisiae (used in this study) against P. multocida and other poultry pathogens have been evaluated previously and their probiotic potentials elucidated17,18.

Information regarding in vivo antimicrobial activity of probiotics strains including LAB and Saccharomyces against P. multocida and S. cerevisiae infections are lacking. However, the inhibitory activity of probiotics consisting of strains of LAB and S. cerevisiae in broilers as recorded in this study indicates that these probiotic strains can be successfully used as alternatives for growth-promoting antibiotics in poultry production. The numbers of enterobacteria in the P. multocida challenged control groups were higher in the ileum and caecum than the unchallenged groups both on days 21 and 28 of the experiment. Probiotic supplemented groups showed higher number of enterobacteria after broiler chickens were supplemented with multi-strain probiotics containing a mixture of L. agilis, L. acidophilus/gallinarum and L. salivarius. The inclusion of strains of Bacillus, Clostridium and Lactobacillus as multi-strain probiotics at the level of 10^6 to 10^9 CFU/kg of diet reportedly suppressed the growth of enterobacteria53–55. Also, probiotics’ antimicrobial effects come from their secretion of antimicrobial compounds including bacteriocins, organic acids (acetic, lactic, propionic, succinic acid, etc.), short-chain fatty acids, hydrogen peroxide and other low molecular weight substances56. The combination of the strains of LAB and yeast used as multi-strain probiotic in this study possibly synergized to form a robust antimicrobial activity against P. multocida and enterobacteria in the gut of the birds supplemented with the study probiotics.

Table 8. Effect of probiotics supplementation on anti-inflammatory gene expression in caecal mucosa of Pasteurella multocida challenged broilers. Values are means of two replicates and standard errors of means. Within each variable, values with the same superscript letter are not significantly different according to Duncan’s multiple range test (P > 0.05). Pro+: challenged probiotic control; PC+: challenged positive control; NC+: challenged negative control. HIF1A hypoxia inducible factor 1 alpha, PTGER2 prostaglandin E receptor 2, TSG-6 tumor necrosis factor- (TNF) stimulated gene-6, Pro+ challenged probiotic, PC+ challenged antibiotic; NC+ challenged control.

| Anti-inflammatory gene | Pasteurella multocida infection | Treatment | Prob+ | PC+ | NC+ | SEM | P value |
|------------------------|--------------------------------|-----------|-------|-----|-----|-----|---------|
| PTGER2                 |                                |           | 1.13^a | 0.75b | 1.02^b | 0.113 | 0.884 |
| HIF1A                  |                                |           | 134.58a | 36.82b | 13.23b | 37.148 | 0.011 |
| TSG-6                  |                                |           | 13.71^a | 9.86b | 1.05^b | 3.747 | 0.003 |

Depending on the strain, the incubation period of P. multocida against S. cerevisiae was determined by the nature and amount of microbial strains used as probiotics. It has been reported that probiotics supplementation may have increased the concentration of VFA in the gut of the birds supplemented with the study probiotics.
Furthermore, these probiotic strains are able to competitively exclude pathogens, hence preventing their attachment to intestinal walls thereby improving intestinal microbial balance. In agreement with Olnood et al. there was a gradual increase in pH concentration from the proximal to the distal GIT regions with probiotic supplemented birds having a more lowered pH level especially in the gizzards\textsuperscript{14,15}. The reduced pH among probiotic supplemented broiler chickens also contributed in the reduction of the numbers of \textit{P. multocida} and enterobacteria.

Dietary conditions and pathological stress commonly determine the haematological changes and health status of birds\textsuperscript{97}. The reduction in major haematological parameters including Hb, PCV, ESR and total RBC in \textit{P. multocida} challenged control groups clearly depicts the onset of anaemia. The occurrence of anaemia in avian cholera infection in poultry has been properly reported\textsuperscript{48}. The cause of anaemia in \textit{P. multocida} challenged birds as recorded in this study may be attributed to bacterial septicaemia. The concentration of total WBC and lymphocytes were also higher in probiotics supplemented birds. Probiotics are known to modulate host immune system response primarily through balance between anti-inflammatory and proinflammatory cytokines\textsuperscript{96}. Similarly, after dietary supplementation of \textit{B. subtilis}-based probiotics, Park and Kim and Lee et al. showed the reduction of coccidiosis clinical signs and improved immune response in broiler chickens challenged with \textit{Eimeria maxima}\textsuperscript{98,99}. The improvement of gut health through the modulation of gut microflora and the modulation of intestinal inflammatory and immune response may significantly inhibit the \textit{P. multocida} colonization and proliferation within the gut hence influencing haptoglobin concentration. The dietary inclusion of probiotics positively influenced haematopoiesis which among others increase the WBC counts, hence enhancing immune cells synthesis which further protects the host against invading pathogens\textsuperscript{98,100}. The presence of congested blood vessels and haemorrhages observed in the lungs, hearts and intestines of \textit{P. multocida} infected birds as a result of fowl cholera is similar to the findings of Shivachandra et al. and Sonone et al.\textsuperscript{98,101}. The supplementation of probiotics as revealed in this study significantly reduced the severity of \textit{P. multocida} infection throughout the experiment, hence, reflecting in the improved haematological parameters as clearly shown.

The reduction in the concentration of total cholesterol, triglycerides, glucose and LDL cholesterol which are major biochemical parameters as reported in our study due to probiotic supplementation agrees with the report of Arun et al. and Al-Kassie et al. who separately reported a significant reduction in total cholesterol, triglycerides and glucose by dietary inclusion of 100 mg/kg diet of \textit{L. sporogenes} probiotic and the combination of probiotic (\textit{Aspergillus niger}) and prebiotic (\textit{Taraxacum officinale}) in broilers\textsuperscript{61,62}. Total cholesterol reduction in probiotic supplemented birds could be as a result of direct assimilation of cholesterol by bacterial cells (which causes reduction in the cholesterol absorption and synthesis in the GIT), 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibition and bile salt hydrolysis\textsuperscript{63,64}. Furthermore, triglyceride reduction in probiotic treated birds may be as a result of increased hydrolysis of bile salt which causes inadequate lipid absorption in the small intestine\textsuperscript{96}. Strains of \textit{Lactobacillus} are known to show high hydrolytic activity on bile salt which consequently leads to bile salts deconjugation within the GIT\textsuperscript{96}. Also, the concentration of total protein was significantly higher in probiotics fed birds. This corroborated with the findings of Dimcho et al. and Alkhalif et al. who reported probiotic effects on total protein concentration in chickens\textsuperscript{102,103}.

Maintaining intestinal health and the integrity of intestinal barrier function is essential for the growth and wellbeing of animals. Several pathogenic factors such as stress and pathogenic bacteria challenges can cause inflammation and damage to the intestinal barrier\textsuperscript{104}. On day 14 post \textit{P. multocida} challenge, greater effects were found for probiotic supplementation on HIF1A, and TSG-6 (\textit{P} < 0.05). The data obtained from this study implies that probiotics supplementation can attenuate inflammatory reactions through the upregulation of the secretion of anti-inflammatory factors.

In the gut of animals, pathogens including \textit{P. multocida} readily cause different degree of inflammatory damage of intestinal epithelial cells by establishing hypoxic microenvironments\textsuperscript{68}. One of the major transcriptional factors that dampen hypoxia-induced inflammation in the gut is HIF1A. HIF1A enhances the synthesis and signaling effects of anti-inflammatory signaling molecules\textsuperscript{69}. TSG-6 is multifunctional protein that has been implicated as having important anti-inflammatory and tissue protective properties\textsuperscript{70}. From this study, HIF1A and TSG-6 in the control treatment with \textit{P. multocida} infection expressed the lowest mRNA profiles, whereas they were upregulated with probiotics supplementation, depicting that these 2 genes are collaboratively associated with either \textit{P. multocida} or probiotics. This is the first work that assessed the expression of these 2 genes on probiotics supplemented chickens infected with \textit{P. multocida}. Unfortunately, no information exists about the expression of these genes in the presence of probiotics and \textit{P. multocida}. However, in a recent work Deng et al. reported the upregulation of HIF1A in probiotic supplemented chickens infected with \textit{Listeria monocytogenes}\textsuperscript{71}. Therefore, further study on the mechanisms responsible for the dampening of inflammation and the upregulation of anti-inflammatory factors, HIF1A and TSG-6 in probiotics supplemented birds is needed. The higher population of Enterobacteria and \textit{P. multocida} in the control group could be associated with the invasion of these bacteria and the pathogenesis of \textit{P. multocida} resulting in the clinical manifestation of \textit{P. multocida} infection and high mortality. A pool of \textit{P. multocida} strains could be evaluated to determine their persistence, spread and multiplication in host tissues and shedding in future research.

**Materials and methods**

**Ethical approval of the study.** The field trial was approved by the Animal Care and Use Committee of the Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, Bangladesh (certification number: ERC/FBST/JUST/2019-32). The health status of birds in the field were routinely monitored by a veterinarian. The birds were kept under controlled environmental conditions in the animal house of Jashore University of Science and Technology, Jashore, Bangladesh, throughout the experimental period.
Authors confirmed that all experiments were performed in accordance with relevant guidelines and regulations and in compliance with the Animal Research: Reporting of in vivo Experiments (ARRIVE) guidelines.

**Strains used for the study and diets.** Five potential probiotic strains previously isolated from broiler chicken and raw milk, and identified using 16S rRNA sequencing as *Lactobacillus plantarum*, *L. fermentum*, *Pediococcus acidilactici*, *Enterococcus faecium* and *Saccharomyces cerevisiae* with suitable probiotic properties including antagonistic activity against broad range of poultry pathogens including *P. multocida*, survivability in simulated gastric juice, bile salts and phenol tolerance, adhesion to ileum epithelial cells, aggregation and hydrophobicity abilities, α-glucosidase inhibitory activity, and competitive exclusion of pathogens were selected for this field trial\textsuperscript{17,18}. Basal diets (starter and grower/finisher) formulated in our laboratory were provided as pellets all through the trial and were based on wheat, soybean meal and corn as shown in Table 9. The five probiotic strains were mixed at equal ratio and added into respective experimental treatments at dose of 10\textsuperscript{8} CFU/kg of diet.

**Experimental design and treatments.** A total of 120 one-day-old Cobb 500 broiler mixed-sex chicks were purchased from a commercial hatchery (NOURISH FARMS, DHAKA, BANGLADESH), weighed individually and randomly assigned to 6 experimental treatments with 2 replicate groups containing 10 chicks each after they were allowed to acclimatize for 2 days. Birds in each treatment were housed in a floor pen containing sawdust litter. Twenty-three hours of light was provided during the first week and then reduced to 18 h throughout the 28 days of the experiment. The 6 experimental treatments adopted in this trial included: (1) negative control (NC\textsuperscript{−}), non-probiotic and unchallenged with *P. multocida*; (2) positive control (PC\textsuperscript{−}), supplemented with doxycycline HCL (0.5 g/mL), non-probiotic and unchallenged with *P. multocida*; (3) probiotic control (Pro\textsuperscript{−}), probiotics supplemented and unchallenged with *P. multocida*; (4) probiotic challenged (Pro\textsuperscript{+}), as probiotics supplemented and challenged with *P. multocida*; (5) positive challenged (PC\textsuperscript{+}), as doxycycline HCL, supplemented and *P. multocida* challenged; and (6) negative challenge (NC\textsuperscript{+}), as non-antibiotic, non-probiotic and challenged with *P. multocida*. In all the treatments, feed and water were provided ad libitum according to the experimental design. Birds in the antibiotic treatments were administered 1 g/L of the doxycycline HCL following the manufacturer’s instructions. Both probiotics and antibiotic were administered between days 3–21 of the experiment (Fig. 2).

**Pathogen challenge.** For the pathogen challenge experiment, strain P-931 of *P. multocida* subsp. *Multocida* ATCC 12945 (capsular Type A) isolated from fowl and known to cause fowl cholera was obtained and used for the experimental infection of birds. Stock culture of *P. multocida* stored at \textminus 80 °C was revived and grown overnight at 37 °C in brain heart infusion broth (LIOFICHEM, ABRUZZI, ITALY) with shaking at 150 rpm. Cells were harvested by washing (8000×g, 10 min) three times with sterile PBS and finally reconstituted in PBS to

| Item                  | Starter | Finisher |
|-----------------------|---------|----------|
| Ingredient, g/kg      |         |          |
| Wheat (26.00%)        | 262.00  | 214.00   |
| Sorghum (15.5%)       | 350.25  | 400.00   |
| Mung beans            | 100.00  | 100.00   |
| Soybean meal (46%)    | 157.00  | 81.50    |
| Limestone             | 15.50   | 16.00    |
| Salt                  | 1.75    | 1.50     |
| Soybean oil           | 2.00    | 2.50     |
| Moisture              | 8.00    | 6.70     |
| Ash                   | 7.60    | 6.00     |
| Dicalcium phosphate   | 1.50    | 1.50     |
| Lysine                | 2.10    | 0.40     |
| Methionine            | 2.10    | 1.30     |
| Threonine             | 0.20    | 0.15     |
| Vitamin and mineral premix\* | 2.50 | 2.50 |
| Crude protein         | 200.00  | 190.00   |
| Crude fibre           | 35.17   | 43.14    |
| Crude fat             | 52.16   | 54.47    |

\*Nutrition value per Kg of vitamin and mineral premix contains 140,000 IU of vitamin A, 70 mg of vitamin E, 3000 IU of vitamin D3, 4 mg of vitamin K, 3 mg of thiamine, 10 mg of vitaminB2, 8 mg of vitamin B6, 0.04 mg of vitamin B12, 48 mg of niacin, 20 mg of calcium d-pantothenate, 500 mg of choline chloride, 0.20 mg of biotin, 1.8 mg of folic acid, 80 mg of manganese, 70 mg of zinc, 50 mg of iron, 10 mg of copper, 3 mg of iodine, 0.4 mg of selenium, and 0.2 mg of cobalt.
At day 14 of the trial, each bird in experimental challenged treatments was orally inoculated with $10^8$ CFU/mL of *P. multocida* as previously described. Birds were examined at 12 h intervals for typical clinical manifestations of fowl cholera until the end of the experiment. Clinical signs and mortality were recorded accordingly. Major clinical signs and symptoms characterizing fowl cholera that were examined included nasal discharge, diarrhoea, lameness, weakness, moribund state, reduced activity, reduced water and feed intake, ruffled feathers and rapid breathing.

**Sample collection and processing.** The individual weight of all the chickens were measured before grouping them into respective treatment pens. Individual bird and leftover feed from each treatment were weighed weekly and the feed intake (FI) and body weight gain (BWG) recorded. Also, feed conversion ratio (FCR; feed intake/weight gain) and mortality (when it occurred) for each treatment were also calculated.

On days 21 and 28 of the experiment, four birds from each pen were selected at random and sacrificed by cervical dislocation after exposing them to overdose of isoflurane anesthesia. All efforts were made to minimize suffering. Visceral organs of each of the sacrificed bird were carefully removed and weighed after opening the abdominal cavity. After emptying the contents into sterile plastic containers, the weight of gizzard, ileum and caecum were recorded. Also, the weight of heart, liver, bursa, spleen, thigh, drumstick, breast, wing and dressing were recorded and expressed as the percentage of the body weight.
analyses per treatment were determined. Obtaining the serum through centrifugation. The average of results obtained from the haemato-biochemical Vitros350 Random Access Chemistry Analyzer (SIEMENS HEALTHCARE DIAGNOSTICS INC, USA) after and checked manually while the biochemical analyses were carried out by Siemens Dimension RxL/Max/SYSAM-XN-1000, XN-550 AL Random Access Haematology Machine (SYSMEX CORPORATION, JAPAN) morphological analysis) on days 21 and 28 of the trial. Haematological assays were conducted using automatic collected from the jugular vein into plane tubes (for biochemical analyses) and anticoagulant tubes (for hae-

biochemical parameters were carried out. Approximately 4 mL of blood samples from each bird sacrificed were target genes and primers sequences are shown in Table 10. The PCR reaction was conducted using POWERUP was performed with the BIO-RAD CFX96 Real-time PCR system (BIO-RAD LABORATORIES, CA, USA). The procedure by Livak and Schmittgen was used to determine the transcriptional profiles of specific gene of interest and were expressed as the relative expression to the housekeeping gene used (2−ΔΔCt).

Determination of digesta pH. Exactly 1 g of fresh digesta samples from gizzard, ileum and caecum of each sacrificed bird on days 21 and 28 were transferred into 9 mL of distilled water in 15 mL tubes and vigorously mixed. After thorough stomaching, the suspension was mixed with a stirrer after which the pH was measured using glass electrode (HANNA INSTRUMENTS, INC., WOONSOCKET, RI, USA).

Haemato-biochemical parameters. Complete blood counts and lipid profile determining the haemato-

biochemical parameters were carried out. Approximately 4 mL of blood samples from each bird sacrificed were collected from the jugular vein into plane tubes (for biochemical analyses) and anticoagulant tubes (for haematological analysis) on days 21 and 28 of the trial. Haematological assays were conducted using automatic SYSAM-XN-1000, XN-550 AL Random Access Haematology Machine (SYSMEX CORPORATION, JAPAN) and checked manually while the biochemical analyses were carried out by Siemens Dimension RxL/Max/ Vitros350 Random Access Chemistry Analyzer (SIEMENS HEALTHCARE DIAGNOSTICS INC, USA) after obtaining the serum through centrifugation. The average of results obtained from the haemato-biochemical analyses per treatment were determined.

Total RNA extraction and mRNA quantification. Approximately 1 g of caecal mucosa was aseptically collected from each of the sacrificed bird for gene quantification. Total RNA was isolated from the caecal tissues samples using the DIRECT-ZOL RNA extraction Kits (ZYMO RESEARCH, IRVINE, USA), following the manufacturer’s protocol, and finally using a Nanodrop 2000 spectrophotometer (THERMO SCIENTIFIC, WILMINGTON, DE), the concentration and purity of RNA were quantified. The purified RNA was converted into complementary DNA (cDNA) using ProtoScript II First Strand cDNA Synthesis Kit (NEW ENGLAND BIO-LABS, INC., MASSACHUSETTS, USA) following the manufacturer’s protocol, and finally using a Nanodrop 2000 spectrophotometer (THERMO SCIENTIFIC INC., MASSACHUSETTS, USA) consisting a total cycling condition consisting of initial heat activation at 95 °C for 10 min, following by 40 cycles of denaturation at 95 °C for 15 s, annealing at 58 °C for 30 s and finally 30 s of extension at 72 °C. The optimum annealing temperature of target and reference genes were determined by the gradient protocol of BIO-RAD CFX96 Real-time PCR system (BIO-RAD LABORATORIES, CA, USA). The target genes and primers sequences are shown in Table 10. The PCR reaction was conducted using POWERUP SYBR Green Master Mix (THERMO FISHER SCIENTIFIC INC., MASSACHUSETTS, USA) consisting a total of 20 μL PCR reaction-mix containing 10 μL 2x SYBR Green PCR Master Mix, 2 μL primers (0.5 μM of 1 μL forward and 1 μL reverse primer) 6 μL template cDNA (~10 ng/μL) and 2 μL nuclease-free water. The qPCR cycling condition consisting of initial heat activation at 95 °C for 10 min, following by 40 cycles of denaturation at 95 °C for 15 s, annealing at 58 °C for 30 s and finally 30 s of extension at 72 °C. The optimum annealing temperature of target and reference genes were determined by the gradient protocol of BIO-RAD CFX96 Real-time PCR System (BIO-RAD LABORATORIES, CA, USA). The procedure by Livak and Schmittgen was used to determine the transcriptional profiles of specific gene of interest and were expressed as the relative expression to the housekeeping gene used (2−ΔΔCt).

Statistical analysis. Data were collected and analyzed by analysis of variance as a completely randomized design using the GLM procedure as described by GRAPHPAD PRISM version 5.0 for Windows (GRAPHPAD SOFTWARE, SAN DIEGO, CA, USA) and SAS software (version 9.4, SAS Institute Inc., Cary, NC). Viable counts of the gizzard, ileum and caecum contents were subjected to logarithmic conversion (Log10) before statis-

Table 10. Primer sequences used for RT-qPCR. ACTB beta-actin, HIF1A hypoxia inducible factor 1 alpha, PTGER2 prostaglandin E receptor 2, TSG-6 tumor necrosis factor- (TNF) stimulated gene-6, F forward, R reverse.

| Gene   | GenBank     | Sequence 5′→3′                                      | Length (bp) |
|--------|-------------|-----------------------------------------------------|-------------|
| HIF1A  | NM_204297.1 | F-CCAGCAGTTTCTCATGCAAT R-AAATGCTGCTAGCCCTGCC       | 215         |
|        |             | F-CCAGCAGTTTCTCATGCAAT R-AAATGCTGCTAGCCCTGCC       | 215         |
| PTGER2 | NM_00108365.1 | F-TTGACAGTACACCTTCTCGTT R-TGAGTTCTATGAGGGCGAGG     | 235         |
| TSG-6  | DQ275160.1  | F-ATGGACAGCGGATTCACCTC R-TCTGAACCCACACAGGCTC       | 219         |
| ACTB   | NM_205518.1 | F-TTACCTGCCCTCTGTGAAGGC R-TCTCAGACTGTGCGGGAAGCTG   | 228         |
tical analysis. All the results were presented as means of two independent experiments, and differences between treatment groups were determined using the Duncan’s multiple range test. Probability values less than 0.05 (P < 0.05) was considered as significant.

Received: 11 October 2020; Accepted: 12 April 2021
Published online: 26 April 2021

References
1. Wilson, B. A. & Ho, M. Pasteurella multocida: From zoonosis to cellular microbiology. Clin. Microbiol. Rev. 26, 631–655. https://doi.org/10.1128/CMR.00024-13 (2013).
2. Wilkie, I. W., Harper, M., Boyce, J. D. & Adler, B. Pasteurella multocida diseases and pathogenesis. Curr. Top. Microbiol. Immunol. 361, 1–22. https://doi.org/10.1007/82_2012_216 (2012).
3. Christensen, J. P., Bojesen, A. M. & Bigaard, M. Chapter 10—Fowl cholera. Poult. Dis. https://doi.org/10.1016/B978-0-7020-2862-5.50015-5 (2008).
4. Petruzzi, B. et al. Biofilm formation and avian immune response following experimental acute and chronic avian cholera due to Pasteurella multocida. Vet. Microbiol. 222, 114–123. https://doi.org/10.1016/j.vetmic.2018.07.005 (2018).
5. Baillot, R., Voisine, P., Côté, L. & Longtin, Y. Deep sternal wound infection due to Pasteurella multocida: the first case report and review of literature. Infection 39, 575–578. https://doi.org/10.1007/s15010-011-0141-5 (2011).
6. Abreu, F. et al. Human Pasteurella multocida infection with likely zoonotic transmission from a pet dog. Spain. Emerg. Infect. Dis. 24, 1145–1146 (2018).
7. Kehrenberg, C., Schulze-Tanzil, G., Martel, J. L., Chalus-Dancla, E. & Schwarz, S. Antimicrobial resistance in Pasteurella and Mannheimia: epidemiology and genetic basis. Vet. Res. 32, 323–339. https://doi.org/10.1051/vetres:2001128 (2001).
8. Khamespour, F., Montaz, H. & Azhdary Manoreh, M. Occurrence of virulence factors and antimicrobial resistance in Pasteurella multocida strains isolated from slaughter cattle in Iran. Front. Microbiol. 5, 3389 (2014).
9. Shivachandra, S. B. et al. Detection of multiple strains of Pasteurella multocida in fowl cholera outbreaks by polymerase chain reaction-based typing. Avian Pathol. 34, 456–462 (2005).
10. Alkhalf, A., Alhaj, M. & Al-homidan, I. Influence of probiotic supplementation on blood parameters and growth performance in broiler chickens. Saudi J. Biol. Sci. 17, 219–225 (2010).
11. Dharma, K. et al. Applications of probiotics in poultry: Enhancing immunity and beneficial effects on production performances and health—A review. J. Immunol. Immunopathol. 13, 1–19 (2011).
12. Fellah, J. S., Jaffredo, T., Nagy, N. & Dunon, D. Development of avian immune system. In Avian Immunology 2nd edn (eds Schat, K. A. et al.) 45–65 (Academic Press, Berlin, 2014).
13. Wilkins, T. & Sequoia, J. Probiotics for gastrointestinal conditions: A summary of the evidence. Am. Fam. Phys. 96, 170–178 (2017).
14. Olmood, C. G., Beski, S. S., Chock, M. & Jii, P. A. Use of Lactobacillus Casomorphin in broilers challenged with Salmonellaflososa. Anim. Nutr. 1, 203–212. https://doi.org/10.1016.j.aninut.2015.07.001 (2015).
15. Smialek, M., Burchardt, S. & Koncicki, A. The influence of probiotic supplementation in broiler chickens on population and carcass contamination with Campylobacter spp. Field study. Res. Vet. Sci. 118, 12–136. https://doi.org/10.1016/j.rvsc.2018.03.009 (2018).
16. Bortoluzzi, C. et al. Bacillus subtilis DSM 32315 supplementation attenuates the effects of Clostridium perfringens challenge on the growth performance and intestinal microbiota of broiler chickens. Microorganism 7, 71. https://doi.org/10.3390/microorganism7030071 (2019).
17. Reuben, R. C., Roy, P. C., Sarkar, S. L., Rubayet-Ul-Alam, A. S. M. & Jahid, I. K. Isolation, characterization, and assessment of lactic acid bacteria toward their selection as poultry probiotics. BMC Microbiol. 53, 1–20. https://doi.org/10.1186/s12866-019-1626-0 (2019).
18. Reuben, R. C., Roy, P. C., Sarkar, S. L., Rubayet-Ul-Alam, A. S. M. & Jahid, I. K. Characterization and evaluation of lactic acid bacteria from indigenous raw milk for potential probiotic properties. J. Dairy Sci. 103, 1223–1237. https://doi.org/10.3168/jds.2019-17092 (2020).
19. Herath, C. et al. Experimental iron-inactivated Pasteurella multocida A: 1 vaccine adjuvanted with bacterial DNA is safe and protects chickens from fowl cholera. Vaccine 28, 2284–2289. https://doi.org/10.1016/j.vaccine.2009.12.068 (2010).
20. Paloca, O. et al. Alternative treatment of serious and mild Pasteurella multocida infection in New ZealandWhite rabbits. BMC Vet. Res. 10, 276 (2014).
21. Varinrank, T., Poolperm, P., Sawada, T. & Shinmanyoe, N. Cross-protection conferred by immunization with an Omp4H-based intranasal fowl cholera vaccine. Avian Pathol. 46, 515–525. https://doi.org/10.1080/03079457.2017.1321105 (2017).
22. Chen, Y., Sun, E., Yang, L., Song, J. & Wu, B. Therapeutic application of bacteriophage PHB02 and its putative depolymerase against Pasteurella multocida capsular type A in mice. Front. Microbiol. 9, 1678. https://doi.org/10.3389/fmicb.2018.01678 (2018).
23. Luo, Q. et al. Protection of chickens against fowl cholera by supernatant proteins of Pasteurella multocida cultured in an iron-restricted medium. Avian Pathol. 48, 221–229. https://doi.org/10.1080/03079457.2019.1568390 (2019).
24. Glisson, J. R., Hofacre, C. L. & Christensen, J. F. Fowl cholera. In Diseases of Poultry 11th edn (eds Sai, Y. M. et al.) 658–676 (Iowa State University Press, Ames, 2003).
25. Xiao, K. et al. Identification of the Avian Pasteurella multocida phoP gene and evaluation of the effects of phoP deletion on virulence and immunogenicity. Int. J. Mol. Sci. 17, 12. https://doi.org/10.3390/ijms17100102 (2016).
26. Bredy, J. P. & Bottlzer, R. G. The effects of six environmental variables on Pasteurella multocida populations in water. J. Wildl. Dis. 25, 232–239 (1989).
27. Wubet, W. et al. Evaluation of inactivated vaccine against fowl cholera developed from local isolates of Pasteurella multocida in Ethiopia. Afr. J. Microbiol. 13, 500–509. https://doi.org/10.5897/AJMR2019.9096 (2019).
28. Mountzouris, K. C. et al. Evaluation of yeast dietary supplementation in broilers challenged or not with Salmonella on growth performance, cecal microbiota composition and Salmonella in ceca, cloacae and carcass skin. Poult. Sci. 94, 2445–2455 (2015).
29. Miechiche, A. C., Foley, S. L., Pavlidis, H. O., McIntyre, D. R. & Ricke, S. C. A review of probiotics against Salmonella in poultry: Current and future potential for microbiome research applications. Front. Vet. Sci. 5, 1–18 (2018).
30. Mancassi, F. R. et al. Dietary Saccharomyces cerevisiae boulardii CNCM I-1079 positively affects performance and intestinal ecosystem in broilers during a Campylobacter jejuni infection. Microorganism 7, 596 (2019).
31. Rahimi, S., Khatariou, S., Fletcher, O. & Grimes, J. L. Effect of a direct-fed microbial and probiotic on performance and intestinal histomorphometry of turkey pouls challenged with Salmonellaand Campylobacter. Poult. Sci. 98, 6572–6578. https://doi.org/10.3382/ps/pea2436 (2019).
32. Cao, G. et al. Effects of a probiotic, Enterococcus faecium, on growth performance, intestinal morphology, immune response, and cecal microflora in broiler chicks. Poult. Sci. 92, 2949–2955 (2013).
33. Huang, L. et al. Effects of the dietary probiotic, Enterococcus faecium NCIMB11811, on the intestinal barrier and system immune status in Escherichia coli O78-challenged Broiler chickens. Probi. Antimicrob. Prot. 11, 946–956. https://doi.org/10.1007/s12602-018-9434-7 (2019).
34. Giannenas, I. et al. Assessment of probiotics supplementation via feed or water on the growth performance, intestinal morphology and microflora of chickens after experimental infection with Eimeria acervulina, Eimeria maxima and Eimeria tenella. Avian Pathol. 43, 209–216. https://doi.org/10.1080/03079457.2014.899430 (2014).
35. Aways, M. M. et al. Immunomodulatory and ameliorative effects of Lactobacillus and Saccharomyces based probiotics on pathological effects of eimeriosis in broilers. Microb. Path. 126, 101–108. https://doi.org/10.1016/j.micpath.2018.10.038 (2019).
36. Deng, Q., Hanyi, S., Yiran, L., Heping, Z. & Ning, L. Effect of dietary Lactobacilli mixture on Listeria monocytogenes infection and virulence property in broilers. Poult. Sci. 99, 3653–3662. https://doi.org/10.3382/ps.2020.03.038 (2020).
37. Drolia, R., Tenguria, S., Durkes, A. C., Turner, J. R. & Bhunia, A. K. Listeria adhesion protein induces intestinal epithelial barrier dysfunction for bacterial translocation. Cell Host Microbe. 23, 470–484 (2018).
38. Rajabi, S., Darban, D., Tabatabaee, R. R. & Hosseini, F. Antimicrobial effect of spore-forming probiotics Bacillus laterosorus and Bacillus megaterium against Listeria monocytogenes. Arch. Microbiol. 202, 2791–2797. https://doi.org/10.1007/s00203-020-02004-9 (2020).
39. Li, Z. et al. Effects of Lactobacillus acidophilus on the growth performance and intestinal health of broilers challenged with Clostridium perfringens. J. Anim. Sci. Biotechnol. 9, 25. https://doi.org/10.1186/s41041-018-0243-3 (2018).
40. Rathnapraba, S., Kanagaraju, P. & Vijayarani, K. Effect of dietary supplementation of probiotic and BMD on the growth performance of broiler chickens challenged with Clostridium perfringens induced necrotic enteritis. Int. J. Chem. Stud. 6, 13–15 (2018).
41. Olnood, C. G., Beski, S. S. M., Choct, M. & Ji, P. Novel probiotics: Their effects on growth performance, gut development, microbial community and activity of broiler chickens. Anim. Nutr. 1, 184–191. https://doi.org/10.1016/j.aninu.2015.07.003 (2015).
42. Park, J. H. & Kim, I. H. The effects of the supplementation of Bacillus subtilis RX7 and B2A strains on the performance, blood profiles, intestinal Salmonella concentration, noxious gas emission, organ weight and breast meat quality of broiler challenged with Salmonella typhimurium. J. Anim. Physiol. Anim. Nutr. 99, 326–334 (2015).
43. Zhang, Z. F., Cho, J. H. & Kim, I. H. Effects of Bacillus subtilis WEB-MO2 on growth performance, relative immune organ weight, gas concentration in excreta, and intestinal microbial. Shedding in broiler chickens. Livestock Sci. 155, 343–347 (2013).
44. Pedroso, A. A. et al. Performance and organ morphology of broilers fed microbial or antimicrobial additives and raised in batteries of floor pens. Rev. Bras. Cienc. Avic. 5, 2–10 (2003).
45. van Dijk, J. E., Huisman, J. & Koninkx, J. F. Structure and functional aspects of a healthy gastrointestinal tract. In Health of the Gastrointestinal Tract (eds Blook, M. C. et al.) 325–346 (Blackwell Publishing, 2010).
46. Pelicano, E. R. L. Regulation of CD11b by HIF-1a and the STAT3 signaling pathway contributes to the immunosuppressive function of tumor-associated macrophages. Mol. Immunol. 111, 162–171. https://doi.org/10.1016/j.molimm.2019.04.005 (2019).
47. Fuji, M. et al. HIF1α inhibits LPS-mediated induction of CEBPβ suppression in human dental pulp cells. Biochem. Biophys. Res. Commun. 522, 308–314. https://doi.org/10.1016/j.bbrc.2019.11.032 (2020).
48. Day, A. J. & Milner, C. M. TSG-6: A multifunctional protein with anti-inflammatory and tissue-protective properties. Matrix Biol. 78–79, 60–83. https://doi.org/10.1016/j.matbio.2018.01.011 (2019).
49. Gao, J., Zhang, H. J. & Yu, S. H. Effects of yeast culture in broiler diets on performance and immunomodulatory functions. Poult. Sci. 87, 1377–1384 (2008).
50. Engberg, R. M., Steenfeldt, S., Hedemann, M. S. & Jensen, B. B. The influence of whole wheat and xylanase on broiler performance and microbial composition and activity in the digestive tract. Poult. Sci. 83, 925–938 (2004).
Acknowledgements

This research was supported by the Bangladesh Academy of Science under BAS-USDA program with Grant code number LSc-33.

Author contributions

R.C.R. performed all experiments and drafted the manuscript. S.L.S. designed the study and edited the manuscript. H.I. and A.A.S. performed the molecular analysis and results interpretation. P.C.R. was collected and interpreted data, and revised manuscript. I.K.J. designed the study, coordinated the research and revised the manuscript. All the participating authors read and approved the submitted manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to I.K.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021